These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28794345)

  • 1. Heparin Cofactor II: A Novel Plausible Link of Obesity and Diabetes with Thrombosis.
    Hasegawa Y; Ishigaki Y
    J Atheroscler Thromb; 2017 Dec; 24(12):1202-1203. PubMed ID: 28794345
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin cofactor II is degraded by heparan sulfate and dextran sulfate.
    Saito A
    Biochem Biophys Res Commun; 2015 Feb; 457(4):585-8. PubMed ID: 25600805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.
    Tollefsen DM
    Semin Thromb Hemost; 1990 Apr; 16(2):162-8. PubMed ID: 2191430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
    Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The second cofactor of heparin].
    Sie P
    Ann Biol Clin (Paris); 1987; 45(2):181-3. PubMed ID: 3619144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis].
    Marbet GA; Zbinden B; Duckert F
    Schweiz Med Wochenschr; 1988 Oct; 118(43):1586-8. PubMed ID: 3238395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle modification strategies to counteract the world epidemic growth of obesity and diabetes.
    De Feo P; Boris JM; Maffeis C
    Biomed Res Int; 2014; 2014():640409. PubMed ID: 25610870
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct thrombin inhibitors: pharmacology and clinical relevance.
    Kam PC; Kaur N; Thong CL
    Anaesthesia; 2005 Jun; 60(6):565-74. PubMed ID: 15918828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodology and clinical significance of heparin cofactor II. Probable heparin cofactor II deficiency in a patient with cerebrovascular thrombosis.
    Tran TH; Zbinden B; Lämmle B; Duckert F
    Semin Thromb Hemost; 1985 Oct; 11(4):342-6. PubMed ID: 3840916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated expression of heparin cofactor II inhibits thrombin-induced cellular responses in fibroblasts and vascular smooth muscle cells.
    Hayakawa Y; Hirashima Y; Yamamoto H; Hayashi N; Kurimoto M; Kuwayama N; Endo S
    Thromb Res; 2005; 116(4):357-63. PubMed ID: 16038721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro.
    Buchanan MR; Maclean GA; Brister SJ
    Thromb Haemost; 2001 Sep; 86(3):909-13. PubMed ID: 11583326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Natural and synthetic inhibitors of thrombin. I. Natural inhibitors].
    Kibirev VK; Gershkovich AA
    Ukr Biokhim Zh (1999); 1999; 71(1):5-15. PubMed ID: 10457984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparin cofactor II inhibits thrombin-stimulated prostacyclin production by cultured vascular smooth muscle cells].
    Hayashi T; Sakuragawa N
    Rinsho Byori; 1992 Mar; Suppl 92():201-6. PubMed ID: 1583774
    [No Abstract]   [Full Text] [Related]  

  • 17. The anticoagulant and antithrombotic mechanisms of heparin.
    Gray E; Hogwood J; Mulloy B
    Handb Exp Pharmacol; 2012; (207):43-61. PubMed ID: 22566220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of heparin cofactor II].
    Takahashi K; Yamagishi R; Niwa M; Sakuragawa N
    Rinsho Byori; 1987 Apr; Spec No 70():181-6. PubMed ID: 3302388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.